Non-invasive imaging of breast cancer: synthesis and study of novel near-infrared fluorescent estrogen conjugate

Jose, Iven; Vishnoi, Gargi; Deodhar, Kodand; Desai, U.B.

doi:10.1117/12.589571

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristic peaks of UV absorption for free DOX and ICG appear at 490 nm and 750–800 nm, respectively. 67 , 68 To verify whether DOX and ICG were successfully encapsulated into PDA@Lipo/DOX/ICG, we characterized the formulation by UV-vis-NIR spectroscopy, and the characteristic peaks of free DOX and ICG were observed in PDA@Lipo/DOX/ICG ( Figure 2C ). The blank carrier PDA@Lipo has broad-spectrum absorption characteristics in the range of 350–850 nm, and its intensity is proportional to the concentration ( Supplementary Figure S1c ).…”

Section: Resultsmentioning

confidence: 99%

“…Notably, there is a slight red-shift from 780 nm to 815 nm in the absorption spectra of PDA@Lipo/DOX/ICG compared to that of free ICG, which can be ascribed to the close-packed ICG in the NPs or the aggregation of ICG induced by the addition of DOX, and the aggregated ICG absorbs at a longer wavelength compared to a single ICG molecule. 68–70 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy

Lu¹,

Liu²,

Hu³

et al. 2023

IJN

View full text Add to dashboard Cite

Introduction Drug delivery systems (DDSs) based on liposomes are potential tools to minimize the side effects and substantially enhance the therapeutic efficacy of chemotherapy. However, it is challenging to achieve biosafe, accurate, and efficient cancer therapy of liposomes with single function or single mechanism. To solve this problem, we designed a multifunctional and multimechanism nanoplatform based on polydopamine (PDA)-coated liposomes for accurate and efficient combinatorial cancer therapy of chemotherapy and laser-induced PDT/PTT. Methods ICG and DOX were co-incorporated in polyethylene glycol modified liposomes, which were further coated with PDA by a facile two-step method to construct PDA-liposome nanoparticles (PDA@Lipo/DOX/ICG). The safety of nanocarriers was investigated on normal HEK-293 cells, and the cellular uptake, intracellular ROS production capacity, and combinatorial treatment effect of the nanoparticles were assessed on human breast cancer cells MDA-MB-231. In vivo biodistribution, thermal imaging, biosafety assessment, and combination therapy effects were estimated based on MDA-MB-231 subcutaneous tumor model. Results Compared with DOX·HCl and Lipo/DOX/ICG, PDA@Lipo/DOX/ICG showed higher toxicity on MDA-MB-231 cells. After endocytosis by target cells, PDA@Lipo/DOX/ICG produced a large amount of ROS for PDT by 808 nm laser irradiation, and the cell inhibition rate of combination therapy reached up to 80.4%. After the tail vein injection (DOX equivalent of 2.5 mg/kg) in mice bearing MDA-MB-231 tumors, PDA@Lipo/DOX/ICG significantly accumulated at the tumor site at 24 h post injection. After 808 nm laser irradiation (1.0 W/cm 2 , 2 min) at this timepoint, PDA@Lipo/DOX/ICG efficiently suppressed the proliferation of MDA-MB-231 cell and even thoroughly ablated tumors. Negligible cardiotoxicity and no treatment-induced side effects were observed. Conclusion PDA@Lipo/DOX/ICG is a multifunctional nanoplatform based on PDA-coated liposomes for accurate and efficient combinatorial cancer therapy of chemotherapy and laser-induced PDT/PTT.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%